Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

108.77 -1.48 (-1.34%)
Streaming Delayed Price Updated: 1:22 PM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
News headline image
Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a... 
Via StockStory
News headline image
Macroeconomic Headwinds and Shifting Demand Force Healthcare Giants to Trim 2026 Outlooks
As the first quarter of 2026 draws to a close, the healthcare and life sciences sectors are grappling with a "new normal" defined by capital conservatism and geopolitical friction. Industry... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Profitable Stocks on Our Watchlist and 1 We Avoid
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
Abbott Laboratories (NYSE:ABT) Emerges as a Top Dividend Stock with Strong Fundamentals ↗
Via Chartmill
News headline image
The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"
As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
2 Reasons to Like ABT and 1 to Stay Skeptical
Over the last six months, Abbott Laboratories’s shares have sunk to $116.31, producing a disappointing 11.5% loss - a stark contrast to the S&P 500’s 7.7% gain. This was partly driven by its softer... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time ↗
Abbott Laboratories is delivering double-digit percentage earnings growth along with a dependable dividend. 
Via The Motley Fool
Topics Cannabis Initial Public Offering
News headline image
The Great Unlocking: Medtronic’s Strategic Pivot and the MiniMed Spin-Off
Date: February 24, 2026 By: Financial Research Analyst Introduction For years, Medtronic plc (NYSE: MDT) was viewed by Wall Street as a reliable but sluggish giant—a "Dividend Aristocrat" that offered... 
Via Finterra
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Abbott Labs: A Boring Dividend Machine That Could Quietly Make You Rich ↗
"Boring" may be just what the doctor ordered in this volatile market. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Medtronic Hits 10-Quarter High: PFA Dominance and Robotic Surges Signal a New Era for MedTech
In a definitive sign that the medical technology sector has moved past its post-pandemic stagnation, Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for the third... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Boston Scientific’s $14.5B Penumbra Mega-Merger: A Strategic Reshaping of the Medtech Landscape
On January 15, 2026, the medical technology sector witnessed its most significant seismic shift in years as Boston Scientific Corporation (NYSE:BSX) announced a definitive agreement to acquire... 
Via MarketMinute
News headline image
Medtronic Hits Ten-Quarter Growth Peak in Q3 Fiscal 2026, Signaling Resurgence in MedTech Sector
Medtronic (NYSE: MDT) reported its strongest enterprise revenue growth in ten quarters for its fiscal third quarter of 2026, marking a significant turning point for the medical technology giant. The... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
3 Large-Cap Stocks with Solid Fundamentals
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
News headline image
Insulet (PODD) Shakes the Market with Q4 Earnings Beat as Omnipod 5 Dominance Continues
Insulet Corporation (NASDAQ:PODD) delivered a commanding performance in its fourth-quarter earnings report released today, February 18, 2026. The medical device leader announced an adjusted earnings... 
Via MarketMinute
Topics Earnings
News headline image
Medtronic (MDT): The Sleeping Giant Awakes with Strong Q3 FY26 Momentum
Today’s Date: February 17, 2026 Introduction Medtronic plc (NYSE: MDT) has long been the sleeping giant of the medical technology sector. For years, the Dublin-domiciled powerhouse was viewed by Wall... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
2 of Wall Street’s Favorite Stocks with Competitive Advantages and 1 We Turn Down
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever ↗
Abbott is the name behind many well-known products. 
Via The Motley Fool
News headline image
1 Reason I'm Never Selling AbbVie Stock ↗
This Dividend King has staying power. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pure-Play Pivot: Decoding Becton Dickinson’s (BDX) Q1 Results and the $17.5B Waters Combination
Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5... 
Via Finterra
Topics Artificial Intelligence Economy Product Recall
News headline image
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal ↗
Via MarketBeat
News headline image
Navigating the MedTech Correction: A Deep-Dive into Boston Scientific (NYSE: BSX)
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left... 
Via Finterra
Topics Product Recall World Trade
News headline image
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered ↗
AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Dividend King to Buy With $150 ↗
The stock is near its 52-week low. 
Via The Motley Fool
News headline image
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist ↗
These market giants make great long-term investments. 
Via The Motley Fool
News headline image
5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call
Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this... 
Via StockStory
Topics Earnings
News headline image
3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗
Investors' reaction to this Dividend King's Q4 revenue miss was overdone. 
Via The Motley Fool
Topics Earnings
News headline image
The Best Dividend Stocks to Buy and Hold Forever ↗
These stocks offer highly attractive dividends and staying power. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.